Balachandar Nedumaran1, Pratyaydipta Rudra2, Jeanette Gaydos3, Sushil Kumar4, Randall B Meacham1, Ellen L Burnham3, Anna P Malykhina5. 1. Division of Urology, Department of Surgery, University of Colorado Denver, Aurora, CO. 2. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO. 3. Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, Aurora, CO. 4. Cardiovascular Pulmonary Research Laboratories, Department of Pediatrics and Medicine, University of Colorado Denver, Aurora, CO. 5. Division of Urology, Department of Surgery, University of Colorado Denver, Aurora, CO. Electronic address: Anna.Malykhina@ucdenver.edu.
Abstract
OBJECTIVE: To evaluate the differences in the composition and quantities of urine peptides in regular cannabis users and nonusers by liquid chromatography tandem mass spectrometry analysis. MATERIALS AND METHODS: Urine specimens from healthy control subjects and cannabis users were utilized to identify the differences in the number and quantity of urine proteins by liquid chromatography tandem mass spectrometry analysis. Significantly altered proteins were determined by a permutation testing statistical method. Heat map, dendrogram, pathway, and network analyses were performed to assess the degree of expression and the potential relationships between proteins in both groups. RESULTS: A total of 1337 proteins were detected in both groups with 19 proteins being significantly altered in cannabis users. Innate immunity and carbohydrate metabolic pathways were highly linked with upregulated proteins in the cannabis group. Additionally, 91 proteins were present and 46 proteins were absent only in cannabis users in comparison with the control cohort. Our results suggest that regular use of cannabis is associated with significant alterations in a number of urinary peptides, with a large number of proteins present or absent only in cannabis users. Pathway analyses demonstrated an increased immune response in cannabis users compared with controls. CONCLUSION: Our observations potentially indicate activation (or inhibition) of specific signaling pathways in the lower urinary tract during chronic exposure to exogenous cannabinoids. Our study provides initial proteomic knowledge for future investigations on the potential role of exocannabinoids in the development of intravesical therapies to treat lower urinary tract disorders.
OBJECTIVE: To evaluate the differences in the composition and quantities of urine peptides in regular cannabis users and nonusers by liquid chromatography tandem mass spectrometry analysis. MATERIALS AND METHODS: Urine specimens from healthy control subjects and cannabis users were utilized to identify the differences in the number and quantity of urine proteins by liquid chromatography tandem mass spectrometry analysis. Significantly altered proteins were determined by a permutation testing statistical method. Heat map, dendrogram, pathway, and network analyses were performed to assess the degree of expression and the potential relationships between proteins in both groups. RESULTS: A total of 1337 proteins were detected in both groups with 19 proteins being significantly altered in cannabis users. Innate immunity and carbohydrate metabolic pathways were highly linked with upregulated proteins in the cannabis group. Additionally, 91 proteins were present and 46 proteins were absent only in cannabis users in comparison with the control cohort. Our results suggest that regular use of cannabis is associated with significant alterations in a number of urinary peptides, with a large number of proteins present or absent only in cannabis users. Pathway analyses demonstrated an increased immune response in cannabis users compared with controls. CONCLUSION: Our observations potentially indicate activation (or inhibition) of specific signaling pathways in the lower urinary tract during chronic exposure to exogenous cannabinoids. Our study provides initial proteomic knowledge for future investigations on the potential role of exocannabinoids in the development of intravesical therapies to treat lower urinary tract disorders.
Authors: Vikas Tyagi; Brian J Philips; Ruthie Su; Marc C Smaldone; Vickie L Erickson; Michael B Chancellor; Naoki Yoshimura; Pradeep Tyagi Journal: J Urol Date: 2009-02-23 Impact factor: 7.450
Authors: Martijn J Wilmer; Erik I Christensen; Lambertus P van den Heuvel; Leo A Monnens; Elena N Levtchenko Journal: Am J Kidney Dis Date: 2008-05-02 Impact factor: 8.860
Authors: Morteza Abyadeh; Vivek Gupta; Joao A Paulo; Veer Gupta; Nitin Chitranshi; Angela Godinez; Danit Saks; Mafruha Hasan; Ardeshir Amirkhani; Matthew McKay; Ghasem H Salekdeh; Paul A Haynes; Stuart L Graham; Mehdi Mirzaei Journal: Biomolecules Date: 2021-09-27